Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

United States

Childrens of Alabama, Birmingham, Alabama

Children's Hospital of Los Angeles, Los Angeles, California

Children's National Hospital, Washington D.C., District of Columbia

Lurie Children's Hospital of Chicago, Chicago, Illinois

University of Chicago, Chicago, Illinois

Riley Hospital for Children/Indiana University, Indianapolis, Indiana

Johns Hopkins University, Baltimore, Maryland

National Cancer Institute/ National Institutes of Health, Bethesda, Maryland

Boston Children's Hospital, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

University of Texas, Southwestern, Dallas, Texas